Latest News

Simbec-Orion and Avance Clinical recently announced the signature of a Memorandum of Understanding (MOU), marking a pivotal step in their strategic collaboration.

The FDA’s Project Optimus aims to revolutionise dose optimisation in early-phase oncology drug development, focusing on selecting doses that minimise toxicity while maximising efficacy and tolerability. This is a significant undertaking that requires drug developers to adopt a collaborative and proactive approach. Partnering with a full-service, experienced CRO can help with implementing the key practical […]

Cancer prevalence is rising globally, and tackling this complex issue requires comprehensive and proactive measures. Traditional approaches to choosing therapy dose, often based on cytotoxic chemotherapy, may result in doses being too high or too low, causing unnecessary toxicity levels or not providing enough benefit to patients. Project Optimus, introduced by the FDA’s Oncology Center […]

Will you be at BioWales Goes West? Our Senior Project Manager Tom Calverley and his colleague, Laboratory Project Manager Adam Chessun will be going along to learn about the existing and potential new collaborations between Wales and the South-West. You can register to attend too, just use this link https://mediwales.com/event/biowales-goes-west/

Simbec-Orion is proud to deploy ClinSpark®, a state-of-the-art electronic data capture platform, purpose-built to optimise Phase I studies. This addition strengthens our suite of technology systems, reinforcing our commitment to innovation and excellence.

Our delegates are delighted to be participating in the 11th Annual Clinical Trials in Oncology meeting in Munich on December 3-4. They would be pleased to meet you for a coffee and hear about your next oncology trial, perhaps we can help with some of the challenges you are facing? Contact us to start the […]